atezolizumab + bevacizumab + cyclophosphamide

**Atezolizumab + bevacizumab + cyclophosphamide** is an investigational combination regimen used primarily in the context of clinical trials for cancer therapy. - **Atezolizumab** is a monoclonal antibody targeting the immune checkpoint protein PD-L1, inhibiting the interaction with PD-1 and B7.1 to activate antitumor immune responses (checkpoint inhibitor, immunotherapy)[1][3]. - **Bevacizumab** is a monoclonal antibody that binds to vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and tumor blood vessel formation (targeted therapy)[1][3]. - **Cyclophosphamide** is a small molecule alkylating agent that crosslinks DNA, causing cell death and immunosuppression; it is used in numerous regimens against various cancers[2][4]. This three-drug combination has potential applications in solid tumors, especially those where atezolizumab + bevacizumab is already established (e.g., hepatocellular carcinoma), and cyclophosphamide is added to enhance antitumor efficacy or modulate the immune microenvironment.